The Long and Winding Road for Breast Cancer Biomarkers to Reach Clinical Utility.

The Long and Winding Road for Breast Cancer Biomarkers to Reach Clinical Utility.
Clin Cancer Res. 2020 Aug 28;:
Authors: Hunter NB, Kilgore MR, Davidson NE
Abstract
Tumor data from the ABCGS5 trial of chemotherapy versus endocrine therapy for premenopausal ER+ breast cancer supports molecular subtyping by Ki-67 immunochemistry as a prognostic marker. But while this tissue was handled uniformly, Ki67 testing overall is unstandardized, complicating clinical utility. Increasing potential biomarkers herald more challenges in biomarker validation.
PMID: 32859655 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - August 27, 2020 Category: Cancer & Oncology Authors: Hunter NB, Kilgore MR, Davidson NE Tags: Clin Cancer Res Source Type: research